Bilirubin, the end product of heme catabolism, is taken up from the blood circulation into the liver. This work identifies a high-affinity transport protein mediating the uptake of bilirubin and its conjugates into human hepatocytes. 
Bilirubin, the main bile pigment in most mammals, is the end product of heme catabolism (1) . In the blood circulation, bilirubin is bound to serum albumin, which prevents its potential toxicity thought to be caused by the free ligand (2) . Despite high-affinity binding to albumin, bilirubin is rapidly and selectively taken up into the liver (3, 4) , biotransformed upon conjugation with glucuronate (5), and secreted into bile across the canalicular membrane of hepatocytes by an ATP-dependent conjugate export pump termed multidrug resistance protein 2 (transporter symbol ABCC2) (6, 7) . In addition to a reduction of UDP-glucuronosyl transferase activity (8) , impaired bilirubin uptake from the blood circulation into liver has been suggested to contribute to a subgroup of patients with Gilbert's syndrome (9) , which is characterized by a mild unconjugated hyperbilirubinemia. Uptake of bilirubin by hepatocytes was considered to be a process mediated by specific membrane proteins, although passive diffusion has also been proposed as a possible mechanism (1, 3, 10) . Because of its instability and low solubility in aqueous solution, hepatic uptake of bilirubin was studied predominantly by use of structurally related anionic substances like sulfobromophthalein (BSP) 1 and indocyanine green (ICG) (3, 9, 11, 12) . A transport protein for BSP with a MichaelisMenten constant (K m ) of 1.5 M has been cloned from rat liver (13) and designated as organic anion-transporting polypeptide 1 (rat OATP1). Rat OATP1 belongs to a family of transport proteins (OATP family, symbol SLC21A) mediating the transport of organic anions including bile salts, steroid conjugates, thyroid hormones, prostaglandins, and BSP (14) . For human OATP1 (SLC21A3), which is expressed at high levels in brain and kidney and at a low level in human liver, kinetic studies revealed only a moderate affinity for BSP with a K m value of 20 M (15). In a search for additional OATP isoforms in human liver, we and other groups have recently cloned a new member of this transporter family, human OATP2 (also known as LST1 or OATP-C, gene symbol SLC21A6) (16 -18) . Most recently, we cloned an additional human liver OATP isoform termed OATP8 (gene symbol SLC21A8), which shares 80% identical amino acids with human OATP2 (19) . Antibodies raised against both transport proteins localized them to the basolateral membrane of human hepatocytes (16, 19) . Northern blot analyses demonstrated an apparently exclusive hepatic expression of both transporters (16, 19) . The availability of cell lines stably expressing human OATP2 and OATP8 enabled us to answer the question of whether these two major human hepatic OATP family members are capable of transporting bilirubin and its conjugates from blood across the basolateral membrane into hepatocytes.
EXPERIMENTAL PROCEDURES
Cell Culture and Cell Lines-HEK293 cells were cultured in minimum essential medium (Sigma) supplemented with 10% fetal bovine serum, 100 units/ml penicillin, and 100 g/ml streptomycin at 37°C, 95% humidity, and 5% CO 2 as described recently (16, 19) . HEK-OATP2 cells (16) and HEK-OATP8 cells (19) permanently expressed high levels of human recombinant OATP2 and OATP8, respectively. The GenBank TM /European Molecular Biology Laboratory accession numbers for the sequences of OATP2 and OATP8 are AJ132573 and AJ251506, respectively.
Biosynthesis of [ 3 H]Bilirubin-[
3 H]Bilirubin was obtained biosynthetically in rats in a procedure similar to the one described by Crawford et al. (20) . Two Harlan Sprague-Dawley rats were given an intravenous or intraportal injection of 500 Ci of [3, (6, 7) and purified using radio-HPLC.
Uptake Studies-For uptake assays, cells were seeded in 6-well plates (coated with 0.1 mg/ml poly-D-lysine) at a density of 1.5-2 ϫ 10 6 cells/well and cultured with 10 mM sodium butyrate for 24 h. Before the uptake experiments, cells were washed with uptake buffer (142 mM NaCl, 5 mM KCl, 1 mM KH 2 PO 4 , 1.2 mM MgSO 4 , 1.5 mM CaCl 2 , 5 mM glucose, and 12.5 mM HEPES, pH 7.3). The transport assay was started by the addition of 1 ml of uptake buffer containing 3 H-labeled substrate (18.5-37 MBq/ml) to the cells. 3 H-labeled substrates were obtained from NEN Life Sciences.
[ 3 H]BSP (0.5 TBq/mmol) was obtained by custom synthesis (Hartmann Analytic, Köln, Germany); its purity (Ͼ98%) was confirmed by reverse-phase HPLC analysis on a C 18 Hypersil column (5-m particles; Shandon, Runcorn, United Kingdom) using two different systems. The isocratic elution was performed with 45% methanol/55% water containing 50 mM NaH 2 PO 4 and 5 mM Na 2 SO 4 at pH 2.8. The linear gradient elution was performed from 100% buffer A (45% methanol/55% water containing 2 mM tetrabutylammonium hydroxide at pH 6.0) to 100% buffer B (90% methanol/10% water containing 2 mM tetrabutylammonium hydroxide at pH 6.0). For inhibition studies, inhibitors were included in the uptake buffer. After incubation at 37°C, transport was stopped at different time points by the addition of 1 ml of cold uptake buffer. Cells were subsequently washed three times with uptake buffer and lysed with 1 ml of 0.2% SDS in water. Aliquots (250 l) of the lysate were counted for radioactivity. Protein content was determined by the Lowry method using 100 l of lysate.
Uptake Studies with [ 3 H]Bilirubin-Due to high background binding of [
3 H]bilirubin to the poly-D-lysine-coated plastic dishes, uptake of [ 3 H]bilirubin into transfected cells was measured in cell suspension. Cells were cultured with 10 mM butyrate for 24 h as described previously (16) . For uptake assays, cells were detached from culture flasks by knocking, washed twice with uptake buffer, and resuspended in uptake buffer at a density of 3 ϫ 10 6 cells/ml. [ 3 H]Bilirubin was diluted with human serum albumin (HSA; Sigma; fatty acid-free) in uptake buffer (75,000 -100,000 dpm/ml). Unlabeled bilirubin was added to give the desired final concentrations. Uptake was started by mixing 1 ml of cell suspension with 1 ml of bilirubin/albumin solution to give a final radioactivity of 37,500 -50,000 dpm/ml and stopped at different time points by centrifugation of the mixture at 13,000 rpm for 10 s. Cell pellets were washed twice with 1 ml of uptake buffer containing HSA and lysed in 2 ml of 0.2% SDS in water. Aliquots (300 l) of the lysate were counted for radioactivity. To determine the nonspecific binding of [ 3 H]bilirubin, cells were incubated with [ 3 H]bilirubin in the presence of HSA for 1 min at 4°C. Cell-associated radioactivity measured under this condition was used as a blank and subtracted from all other values. No differences between this method and the method using adherent cells were observed for other substrates like BSP.
Immunoblot Analysis-Preparation of crude membrane fractions from transfected cells and immunoblot analysis were performed as described previously (16, 19) . The polyclonal antibody ESL (16) was used to detect recombinant human OATP2.
RESULTS

Sulfobromophthalein, Monoglucuronosyl Bilirubin, and Bisglucuronosyl Bilirubin Are High-affinity Substrates for Human
OATP2-BSP, a widely used anionic model compound for studies on uptake into the liver, is a high-affinity substrate for OATP2 with a K m value of 140 nM (Fig. 1) . In comparison with OATP8, OATP2 showed a 24-fold higher affinity for BSP (Table  I ). In addition, monoglucuronosyl bilirubin and bisglucuronosyl bilirubin were identified as high-affinity substrates for OATP2 with nanomolar K m values. Monoglucuronosyl bilirubin was also a good substrate for human OATP8 (Table I) . Kinetic properties of additional substrates for OATP2 and OATP8 are summarized in Table I . Despite the remarkable difference in their affinities for BSP, human OATP2 and OATP8 showed similar affinities for 17␤-glucuronosyl estradiol (E 2 17␤G).
OATP2, but not OATP8, Transports Substrates in the Presence of Albumin-An important aspect with regard to BSP uptake mediated by both transporters is the differential influence of HSA. As shown in Fig. 2A , HSA, in a 20-fold molar excess, did not significantly affect OATP2-mediated BSP uptake but abolished OATP8-mediated BSP uptake. One-third of the respective K m value (50 nM for OATP2 and 1 M for OATP8) was chosen as the BSP concentration in these experiments. A similar influence of HSA was observed when BSP uptake was measured for both transporters at a constant BSP concentration (1 M) with varying HSA concentrations (Fig. 2B) . HSA caused only a minor decrease of OATP2-mediated BSP uptake. Uptake assays using 1 M E 2 17␤G as substrate showed that 5 M HSA did not change the uptake rate with OATP2. The OATP2-mediated uptake was not chloride-dependent in the presence or absence of HSA because replacement of chloride in uptake buffer by gluconate had no effect on the rate of uptake. It is well known that many organic anions bind to HSA in the blood circulation, and a particular role of HSA in the hepatic uptake of organic anions has been proposed (22) . It is therefore conceivable that a hepatic transport protein like OATP2 has the ability to extract substrates from HSA. For OATP8, the interaction with HSA is different (Fig. 2) . We have identified four lipophilic organic anions (monoglucuronosyl bilirubin, BSP, E 2 17␤G, and dehydroepiandrosterone 3-sulfate) as 3 Hlabeled substrates for OATP8. These experiments, however, were performed without HSA in the buffer (Table I ). The fact that OATP8 is not capable of extracting substrates from HSA raises the question of the physiological function of OATP8 in the basolateral hepatocyte membrane. From the data obtained thus far, it is feasible that OATP8 functions predominantly under circumstances where the binding capacity of albumin for lipophilic organic anions is exceeded.
Indocyanine Green Inhibits Transport Mediated by OATP2 but not Transport
Mediated by OATP8 -We tested a number of organic anions for their ability to inhibit uptake by human OATP2 and OATP8. ICG did not affect OATP8-mediated E 2 17␤G transport at concentrations up to 10 M (Fig. 3A) inhibited OATP2-mediated uptake in a competitive manner with a K i value of 112 nM. Although BSP and ICG were thought to be taken up into hepatocytes by the same mechanism (3), patients with apparently normal hepatic BSP uptake but delayed ICG clearance have been reported (11) . Our studies raise the possibility that such patients may have a deficiency in OATP2, leading to delayed ICG clearance, but normal OATP8, which may function in BSP uptake under this condition.
Unlike ICG, the drugs pravastatin, rifamycin SV, and rifampicin inhibited both OATP2-and OATP8-mediated uptake of [ 3 H]E 2 17␤G (Fig. 3B) . The HMG-CoA reductase inhibitor pravastatin was a competitive inhibitor of OATP2-mediated transport of E 2 17␤G with an inhibition constant of 53 M. This is in line with a recent study showing that pravastatin is a substrate for human OATP2 with a K m value of about 30 M (17) .
Unconjugated Bilirubin Is Transported by OATP2 in the Presence of Albumin-The fact that BSP, monoglucuronosyl bilirubin, and bisglucuronosyl bilirubin are high-affinity substrates for human OATP2 and the fact that ICG inhibits OATP2-mediated uptake competitively at nanomolar concentrations suggested that OATP2 might be the long-sought uptake transporter for unconjugated bilirubin in the basolateral hepatocyte membrane. We therefore measured [ (12), is about 25 nM. As shown in Fig. 4A ) by a factor of 5.7 (p Ͻ 0.01). When the uptake was determined at 4°C, no significant difference in uptake rates was detected between OATP2-expressing cells and control cells. Uptake of bilirubin mediated by recombinant human OATP2 was concentration-dependent as shown in Fig.  4B . In these experiments, the HSA concentration was kept constant at 20 M so that the bilirubin:HSA ratio did not exceed 0.5. Because of the uncertainty of calculated free bilirubin concentrations (12), the K m value for free unconjugated bilirubin could only be estimated and was about 160 nM. For comparison, we investigated whether OATP8 would also transport unconjugated bilirubin. At the same [ 3 H]bilirubin and HSA concentrations and under the same conditions used for OATP2 (Fig. 4) , no significant uptake of [ 3 H]bilirubin was detected with HEK293 cells expressing human OATP8 (data not shown).
Bilirubin, which was examined as a complex with HSA, inhibited the uptake of E 2 17␤G and BSP by human OATP2, with 50% inhibition at 5 M with E 2 17␤G as substrate and at 20 M with BSP as substrate. Uptake of [ 3 H]bilirubin into HEK-OATP2 cells was strongly inhibited by BSP (Fig. 4C) , demonstrating mutual inhibition of BSP and bilirubin uptake. DISCUSSION We conclude that uptake of bilirubin into human hepatocytes, the first step of its detoxification, is mediated by OATP2, a major transport protein localized to the basolateral membrane of hepatocytes, but not by the isoform OATP8 localized to the same membrane domain. Our conclusion is based on the following experimental data: (a) the structurally and chemically related lipophilic anionic compounds BSP, monoglucuronosyl bilirubin, and bisglucuronosyl bilirubin were highaffinity substrates for OATP2, with nanomolar K m values, whereas OATP8 transported BSP and monoglucuronosyl bilirubin with markedly lower affinity ( Fig. 1 and Table I ); (b) OATP2, but not OATP8, was able to extract substrates from albumin ( Fig. 2) to which bilirubin binds with high affinity; (c) ICG inhibited OATP2 at nanomolar concentrations but exerted no inhibitory effect on OATP8 at concentrations up to 10 M (Fig. 3) ; and (d) [ 3 H]bilirubin uptake by OATP2 was directly demonstrated by uptake studies with OATP2-expressing HEK transfectants (Fig. 4) . Together with previous data, we propose the following scheme for the detoxification and elimination pathway of bilirubin in human liver (Fig. 5) : bilirubin (B) bound to albumin is taken up across the basolateral membrane by OATP2 and conjugated in the hepatocyte by the UDPglucuronosyl transferase 1A (UGT1A1), resulting in monoglucuronosyl bilirubin and bisglucuronosyl bilirubin. Bilirubin glucuronides are finally excreted into bile by the apical conjugate export pump multidrug resistance protein 2 localized to the hepatocyte canalicular (apical) membrane (6, 7).
Our results here establish a carrier-mediated uptake of bilirubin into hepatocytes. However, we do not exclude additional bilirubin uptake through passive diffusion. The differentiation between carrier-mediated and diffusional bilirubin uptake into the liver will be supported by the identification of mutations in the OATP2 (SLC21A6) gene leading to the loss or functional impairment of OATP2 in the basolateral membrane of hepatocytes. Moreover, in view of the fact that current knowledge of the human OATP family is not complete, additional transport proteins may further contribute to the selective uptake of bilirubin from the blood circulation into liver. . 4A ) and conjugated with glucuronate (GA) by UDP-glucuronosyl transferase 1A1 (UGT1A1), resulting in monoglucuronosyl bilirubin (BGA) and bisglucuronosyl bilirubin (B(GA) 2 ) (5). The excretion of BGA and B(GA) 2 is mediated by the apical ATP-dependent conjugate export pump, multidrug resistance protein 2 (symbol ABCC2) (6, 7) .
